ClinicalTrials.gg
WithdrawnNCT02576275Updated Mar 17, 2021

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

A Phase 3 interventional study of Duvelisib and Placebo in Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma and Small Lymphocytic Lymphoma, sponsored by SecuraBio. Withdrawn at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by SecuraBio · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,185 studies in Lymphoma, Follicular with a site in United States — 127 open to participants now, 216 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Enrollment
987th of 1,015
0 · median 38
Started
2015
with 30 others
Phase 3
105 of 1,185
9 open now
Registered
783rd of 1,185
by date

Among the 1,185 studies in Lymphoma, Follicular with a site in United States, this one is the 987th largest by enrollment of the 1,015 interventional ones that give a count, is one of 31 that started in 2015, is one of 105 in phase 3, and was the 783rd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

127 of the 1,185 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

122 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,185 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent non-Hodgkin lymphoma (iNHL).

Read the detailed description

Study IPI-145-22 is an international, multicenter, randomized, double-blind, placebo-controlled, two-arm Phase 3 study designed to evaluate efficacy and safety of DBR vs PBR in subjects with previously-treated iNHL (including follicular lymphoma [FL], small lymphocytic lymphoma [SLL] and marginal zone lymphoma [MZL]).

Approximately 600 subjects will receive 25 mg of duvelisib or placebo, orally BID for 28 day continuous cycles, in combination with 375 mg/m2 of rituximab given on Day 1 of Cycles 1-6 and 90 mg/m2 of bendamustine given on Day 1 and Day 2 of Cycles 1-6. Subjects will receive duvelisib until disease progression or unacceptable toxicity.

03

Conditions studied

  • Indolent Non-Hodgkin's Lymphoma
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Marginal Zone Lymphoma

Keywords

  • Phase 3
  • iNHL
  • Follicular Lymphoma
  • FL
  • PI3K
  • Small Lymphocytic Lymphoma
  • SLL
  • Marginal Zone Lymphoma
  • MZL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of iNHL with one of the following histologic sub-types and grade:

    • Follicular lymphoma (FL)Grade 1, 2, or 3a
    • Small lymphocytic lymphoma (SLL)
    • Marginal zone lymphoma (MZL)( splenic, nodal, or extranodal)
  • Have received the following systemic treatments for iNHL:

    • an anti-CD20 antibody; and
    • chemotherapy
  • At least 1 lesion > 1.5 cm in at least one dimension by computed tomography (CT)/CT-PET or magnetic resonance imaging (MRI)
  • (ECOG) performance status 0 to 2 (corresponds to Performance Status [(KPS) ≥60%])

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3B FL
  • to bendamustine + rituximab therapy or single-agent bendamustine 120 mg/m2, with refractory defined as:

    - Progression of disease while receiving or within 6 months of completing treatment

  • Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known to any of the study drugs
  • Received prior transplant
  • Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor
  • Infection with , , or (HIV).
  • History of tuberculosis treatment within the two years prior to randomization
  • History of chronic liver disease, veno-occlusive disease, or alcohol abuse
  • Ongoing treatment with chronic (e.g., cyclosporine) or systemic > 20 mg of prednisone (or equivalent) daily (QD)
  • Ongoing treatment for systemic bacterial, fungal, or viral infection at screening
  • Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening
  • Concurrent active other than adequately treated non-melanoma skin cancer or lentigo maligna without evidence of invasive disease or adequately treated cervical carcinoma in situ without evidence of disease
  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or a pacemaker within the last 6 months prior to screening
  • History of progressive multifocal leukoencephalopathy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Duvelisib + Rituximab + Bendamustine

    Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg. Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg.

    Drug: Duvelisib · Drug: Rituximab · Drug: Bendamustine

  • Placebo comparator
    Placebo + Rituximab + Bendamustine

    Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib. Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg. Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg.

    Drug: Placebo · Drug: Rituximab · Drug: Bendamustine

Interventions

  • Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles

    Also known as: IPI-145

  • DrugPlacebo

    Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles

  • IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.

    Also known as: Rituxan, MabThera

  • IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.

    Also known as: Treanda, Levact

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: From date of enrollment until the date of first documentation of progression or date of death from any cause, whatever came first, assessed up to 78 months

Secondary outcomes

  1. Complete Response (CRR)

    Time frame: Every 3-6 Cycles (each cycle is 28 days) from date of randomization, until date of first documented progression. Subjects will be evaluated for progression through the primary analysis of the study or 5 years from randomization, whichever is later.

  2. Overall Response Rate (ORR)

    Time frame: Every 3-6 Cycles (each cycle is 28 days) from date of randomization, until date of first documented progression. Subjects will be evaluated for progression through the primary analysis of the study or 5 years from randomization, whichever is later.

  3. Overall Survival (OS)

    Time frame: Every 6 months for up to 5 years from date of randomization

  4. Duration of Response (DOR)

    Time frame: Every 3-6 Cycles (each cycle is 28 days) from date of randomization, until date of first documented progression. Subjects will be evaluated for progression through the primary analysis of the study or 5 years from randomization, whichever is later.

  5. Safety (Treatment- emergent adverse events (TEAEs) and changes in safety laboratory values)

    Time frame: Continuous from informed consent until 30 days from last dose

  6. Pharmacokinetics (PK)

    Evaluate the Duvelisib concentration in plasma sample.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

  7. Pharmacokinetics (PK)

    Evaluate IPI-656 (metabolite) concentration in plasma sample.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

07

Study locations

7 sites
  • Plainville, Connecticut 06062, United States
  • Plantation, Florida 33322, United States
  • Thomasville, Georgia 31792, United States
  • East Setauket, New York 11733-3456, United States
  • Cookeville, Tennessee 38501, United States
  • Knoxville, Tennessee 37909, United States
  • Spokane, Washington 99208, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2015
First posted
Oct 15, 2015
Start
Dec 2015
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02576275
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Oct 15, 2015
Start date
Dec 2015
Primary completion
Nov 2016
Completion
Nov 2016
Last update
Mar 17, 2021

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion